Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.

Item request has been placed!

Item request cannot be made.

Processing Request

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

المؤلفون: Monge S;Monge S;Monge S; Humphreys J; Humphreys J; Nicolay N; Nicolay N; Braeye T; Braeye T; Van Evercooren I; Van Evercooren I; Holm Hansen C; Holm Hansen C; Emborg HD; Emborg HD; Sacco C; Sacco C; Sacco C; Mateo-Urdiales A; Mateo-Urdiales A; Castilla J; Castilla J; Castilla J; Martínez-Baz I; Martínez-Baz I; Martínez-Baz I; de Gier B; de Gier B; Hahné S; Hahné S; Meijerink H; Meijerink H; Kristoffersen AB; Kristoffersen AB; Machado A; Machado A; Soares P; Soares P; Nardone A; Nardone A; Bacci S; Bacci S; Kissling E; Kissling E; Nunes B; Nunes B
المصدر:
Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Apr; Vol. 18 (4), pp. e13292.
نوع النشر :
Journal Article; Research Support, Non-U.S. Gov't
اللغة:
English

معلومة اضافية
- Corporate Authors:
  VEBIS‐EHR Working Group
- المصدر:
  Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE
- بيانات النشر:
  Original Publication: Oxford, UK : Wiley, c2007-
- الموضوع:
  COVID-19*/prevention & control ; COVID-19*/epidemiology ; COVID-19 Vaccines*/immunology ; COVID-19 Vaccines*/administration & dosage ; European Union* ; Hospitalization*/statistics & numerical data ; SARS-CoV-2*/immunology ; Vaccine Efficacy*; Humans ; Aged ; Male ; Aged, 80 and over ; Female ; Retrospective Studies ; Vaccination/statistics & numerical data ; Europe/epidemiology ; Electronic Health Records
- نبذة مختصرة :
  Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
  (© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
- References:
  Euro Surveill. 2023 Feb;28(8):. (PMID: 36820640)
  Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919)
  BMJ. 2023 Jul 25;382:e075286. (PMID: 37491022)
  Euro Surveill. 2024 Jan;29(3):. (PMID: 38240061)
  Euro Surveill. 2024 Jan;29(1):. (PMID: 38179623)
  Lancet Infect Dis. 2023 Dec;23(12):1349-1359. (PMID: 37478877)
  Euro Surveill. 2022 Sep;27(37):. (PMID: 36111555)
  Euro Surveill. 2024 Jan;29(1):. (PMID: 38179626)
  Euro Surveill. 2023 Aug;28(32):. (PMID: 37561053)
- Grant Information:
  RS/2022/DTS/2410 European Centre for Disease Prevention and Control; RS/2022/DTS/24104 European Centre for Disease Prevention and Control; CEECINST/00049/2021/CP2817/CT0001 FCT - Fundação para a Ciência e Tecnologia, I.P.
- Contributed Indexing:
  Keywords: COVID‐19; SARS‐CoV‐2; cohort design; electronic health records; hospitalisation; multicountry study; vaccine effectiveness
- الرقم المعرف:
  0 (COVID-19 Vaccines)
- الموضوع:
  Date Created: 20240424 Date Completed: 20240424 Latest Revision: 20240427
- الموضوع:
  20240427
- الرقم المعرف:
  PMC11040092
- الرقم المعرف:
  10.1111/irv.13292
- الرقم المعرف:
  38654485

تعليقات

No Comments.